IN2014DN08477A - - Google Patents
Info
- Publication number
- IN2014DN08477A IN2014DN08477A IN8477DEN2014A IN2014DN08477A IN 2014DN08477 A IN2014DN08477 A IN 2014DN08477A IN 8477DEN2014 A IN8477DEN2014 A IN 8477DEN2014A IN 2014DN08477 A IN2014DN08477 A IN 2014DN08477A
- Authority
- IN
- India
- Prior art keywords
- treatment
- disclosed
- methods
- cell proliferative
- proliferative disorders
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 102000004000 Aurora Kinase A Human genes 0.000 abstract 1
- 108090000461 Aurora Kinase A Proteins 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 229940123237 Taxane Drugs 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed are methods for the treatment of various cell proliferative disorders. Disclosed in particular are methods for treatment of various cell proliferative disorders by administering a selective inhibitor of Aurora A kinase in combination with taxane based chemotherapy such as paclitaxel or docetaxel.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261613258P | 2012-03-20 | 2012-03-20 | |
| PCT/US2013/032962 WO2013142491A1 (en) | 2012-03-20 | 2013-03-19 | Methods of treating cancer using aurora kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN08477A true IN2014DN08477A (en) | 2015-05-08 |
Family
ID=48048255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN8477DEN2014 IN2014DN08477A (en) | 2012-03-20 | 2013-03-19 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20130303519A1 (en) |
| EP (1) | EP2827855B1 (en) |
| JP (1) | JP6373252B2 (en) |
| KR (1) | KR102128866B1 (en) |
| CN (1) | CN104271129A (en) |
| AU (1) | AU2013235275B2 (en) |
| CA (1) | CA2868024A1 (en) |
| EA (1) | EA036434B1 (en) |
| ES (1) | ES2746946T3 (en) |
| GE (1) | GEP20186900B (en) |
| IL (1) | IL234686B (en) |
| IN (1) | IN2014DN08477A (en) |
| JO (1) | JO3630B1 (en) |
| MA (1) | MA37438A1 (en) |
| MX (1) | MX358411B (en) |
| MY (1) | MY175225A (en) |
| NZ (1) | NZ700744A (en) |
| PH (1) | PH12014502109A1 (en) |
| SG (2) | SG10201607741RA (en) |
| TN (1) | TN2014000387A1 (en) |
| TW (1) | TWI649082B (en) |
| UA (1) | UA117455C2 (en) |
| WO (1) | WO2013142491A1 (en) |
| ZA (1) | ZA201407551B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| WO2016106357A1 (en) * | 2014-12-23 | 2016-06-30 | Millennnium Pharmaceuticals, Inc. | Combination of raf inhibitors and aurora kinase inhibitors |
| WO2017003845A1 (en) * | 2015-07-02 | 2017-01-05 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to selective inhibitors of aurora a kinase |
| CN114681455A (en) * | 2018-08-17 | 2022-07-01 | 深圳微芯生物科技股份有限公司 | Combination of histone deacetylase inhibitor and protein kinase inhibitor and pharmaceutical application thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4099012A (en) | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
| CA1138863A (en) | 1979-02-07 | 1983-01-04 | Norman W. Gilman | Benzazepine-derivatives |
| US4481142A (en) | 1979-02-07 | 1984-11-06 | Hoffmann-La Roche Inc. | Pyrimido-2-benzazepines |
| US4469633A (en) | 1980-05-16 | 1984-09-04 | Hoffmann-La Roche Inc. | N-oxides of 5-oxo-1-phenyl-2-benzazepines |
| EP0273697A3 (en) | 1986-12-30 | 1989-11-29 | Merck & Co. Inc. | 2-benzazepines with 5- and 6- membered heterocyclic rings |
| US5166151A (en) | 1988-03-25 | 1992-11-24 | Merck & Co., Inc. | 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof |
| US5210082A (en) | 1991-05-16 | 1993-05-11 | Merck & Co., Inc. | 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5747487A (en) | 1993-07-29 | 1998-05-05 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| EP0888350A1 (en) | 1996-03-08 | 1999-01-07 | Zeneca Limited | Azolobenzazepine derivatives as neurologically active agents |
| JP2001507349A (en) | 1996-12-23 | 2001-06-05 | セルテック セラピューティックス リミテッド | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
| GB9713087D0 (en) | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
| IL135303A0 (en) | 1997-09-29 | 2001-05-20 | Meiji Seika Kaisha | Tricyclic triazolobenzazepine derivatives, process for producing the same and antiallergic agents |
| US6277844B1 (en) | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
| AU4841700A (en) | 1999-05-12 | 2000-11-21 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
| ATE346064T1 (en) | 2000-09-15 | 2006-12-15 | Vertex Pharma | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS |
| ATE354573T1 (en) | 2000-12-21 | 2007-03-15 | Vertex Pharma | ßPYRAZOLE COMPOUNDS THAT ARE SUITABLE AS PROTEIN KINASE INHIBITORS |
| SI20848A (en) | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Pharmaceutical formulation containing atorvastatin calcium |
| US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
| DE10135457A1 (en) | 2001-07-20 | 2003-02-06 | Adc Automotive Dist Control | Optical sensor device for use in automobile positioned behind transparent panel with lamella elements between latter and optical transmitter-receiver |
| CN100418955C (en) | 2001-08-09 | 2008-09-17 | 埃科特莱茵药品有限公司 | Novel Benzo-fused Heterocycles |
| CN1897950A (en) | 2003-10-14 | 2007-01-17 | 惠氏公司 | Fused aryl and heteroaryl derivatives and methods of use |
| AU2005213472A1 (en) | 2004-02-10 | 2005-08-25 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent |
| EP2261226B1 (en) | 2004-05-14 | 2015-04-01 | Millennium Pharmaceuticals, Inc. | Methods for preparing aurora kinase inhibitors |
| MX2007005857A (en) | 2004-11-17 | 2007-10-10 | Mikana Therapeutics Inc | Kinase inhibitors. |
| EP1836188A1 (en) | 2004-12-30 | 2007-09-26 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
| MX2008008320A (en) | 2005-12-23 | 2008-09-03 | Smithkline Beecham Corp | Azaindole inhibitors of aurora kinases. |
| JP2009523784A (en) | 2006-01-16 | 2009-06-25 | ジュビラント・オルガノシス・リミテッド | Stable pharmaceutical preparation of acid labile compound and method for producing the same |
| CL2007000667A1 (en) | 2006-03-14 | 2008-03-14 | Ranbaxi Lab Ltd | PHARMACEUTICAL COMPOSITION THAT INCLUDES ACID 7- [2- (4-FLUOROPHENYL) -5-ISOPROPIL-3-PHENYL-4 - [(4-HYDROXIMETHYLPHENAMINE) CARBONYL] PIRROL-1-IL] -3,5-DIHYDROXI-HEPTANOIC OR A SALT AND AT LEAST A STABILIZING AGENT; PREPARATION PROCEDURE, USEFUL IN E |
| DE102006012301A1 (en) | 2006-03-15 | 2007-09-20 | Cemag-Anlagenbau-Dessau Gmbh | Production of cement clinker |
| WO2008021038A2 (en) | 2006-08-09 | 2008-02-21 | Millennium Pharmaceuticals, Inc. | Pyridobenzazepine compounds and methods for inhibiting mitotic progression |
| JP2010508353A (en) | 2006-10-31 | 2010-03-18 | アキリオン ファーマシューティカルズ，インコーポレーテッド | Elvucitabine pharmaceutical composition |
| CL2007003244A1 (en) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | COMPOUNDS DERIVED FROM PIRIMIDO [5,4-D] [2] BENZAZEPINA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER. |
| AR065802A1 (en) | 2007-03-22 | 2009-07-01 | Schering Corp | FORMULATIONS OF TABLETS CONTAINING SALTS OF 8- [(1- (3,5- BIS- (TRIFLUOROMETIL) FENIL) -ETOXI) - METHYL) -8- PHENYL -1, 7- DIAZA- SPIRO [4,5] DECAN - 2- ONA AND TABLETS PREPARED FROM THESE |
| US20090203671A1 (en) | 2007-11-27 | 2009-08-13 | Abbott Laboratories | Method of treating cancer |
| WO2009114703A2 (en) * | 2008-03-12 | 2009-09-17 | Fox Chase Cancer Center | Combination therapy for the treatment of cancer |
| KR102080429B1 (en) | 2008-06-26 | 2020-02-21 | 안테리오스, 인코퍼레이티드 | Dermal delivery |
| JO3635B1 (en) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | Solid pharmaceutical compositions and processes for their production |
| JO3434B1 (en) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders |
| RU2012140021A (en) * | 2010-02-19 | 2014-03-27 | Миллениум Фармасьютикалз, Инк. | CRYSTAL FORMS 4 - {[9-CHLOR-7- (2-FLUOR-6-METHOXYPHENYL) -5H-PYRIMIDO [5,4-d] [2] BENZAZEPIN-2-IL] AMINO} -2-SODIUM METHOZIBENZOATE |
| US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
-
2013
- 2013-03-14 US US13/804,570 patent/US20130303519A1/en not_active Abandoned
- 2013-03-18 JO JOP/2013/0075A patent/JO3630B1/en active
- 2013-03-19 AU AU2013235275A patent/AU2013235275B2/en active Active
- 2013-03-19 MX MX2014011324A patent/MX358411B/en active IP Right Grant
- 2013-03-19 EA EA201491727A patent/EA036434B1/en not_active IP Right Cessation
- 2013-03-19 NZ NZ700744A patent/NZ700744A/en not_active IP Right Cessation
- 2013-03-19 SG SG10201607741RA patent/SG10201607741RA/en unknown
- 2013-03-19 MY MYPI2014702635A patent/MY175225A/en unknown
- 2013-03-19 UA UAA201411324A patent/UA117455C2/en unknown
- 2013-03-19 SG SG11201405621UA patent/SG11201405621UA/en unknown
- 2013-03-19 KR KR1020147028776A patent/KR102128866B1/en active Active
- 2013-03-19 MA MA37438A patent/MA37438A1/en unknown
- 2013-03-19 CA CA2868024A patent/CA2868024A1/en not_active Abandoned
- 2013-03-19 WO PCT/US2013/032962 patent/WO2013142491A1/en not_active Ceased
- 2013-03-19 CN CN201380015806.1A patent/CN104271129A/en active Pending
- 2013-03-19 GE GEAP201313599A patent/GEP20186900B/en unknown
- 2013-03-19 ES ES13714455T patent/ES2746946T3/en active Active
- 2013-03-19 JP JP2015501852A patent/JP6373252B2/en active Active
- 2013-03-19 EP EP13714455.6A patent/EP2827855B1/en active Active
- 2013-03-19 IN IN8477DEN2014 patent/IN2014DN08477A/en unknown
- 2013-03-20 TW TW102109912A patent/TWI649082B/en active
-
2014
- 2014-09-15 TN TNP2014000387A patent/TN2014000387A1/en unknown
- 2014-09-16 IL IL234686A patent/IL234686B/en active IP Right Grant
- 2014-09-22 PH PH12014502109A patent/PH12014502109A1/en unknown
- 2014-10-17 ZA ZA2014/07551A patent/ZA201407551B/en unknown
-
2015
- 2015-09-03 US US14/844,270 patent/US10213436B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013501314A1 (en) | Anticancer therapy with dual aurora kinase / mek inhibitors | |
| PH12016502066A1 (en) | Methods of treating bladder cancer | |
| MX373959B (en) | Improved compositions for treating muscular dystrophy | |
| MX382017B (en) | METHODS FOR THE TREATMENT OF PANCREATIC CANCER. | |
| WO2013177187A3 (en) | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents | |
| MX378934B (en) | Methods of treating bladder cancer | |
| MX393818B (en) | COMBINATION THERAPIES FOR CANCER TREATMENT. | |
| MX2014012477A (en) | Pyrrolopyrazone inhibitors of tankyrase. | |
| NZ628294A (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
| EA201490559A1 (en) | COMPOSITION FOR THE TREATMENT OF Fistula | |
| PH12016502291A1 (en) | Indolizine derivatives as phosphoinositide 3-kinases inhibitors | |
| MX2019014986A (en) | Methods of treatment of cancer by continuous infusion of coenzyme q10. | |
| MY181602A (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
| WO2013134407A3 (en) | Procaspase 3 activation by combination therapy | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| GB201302343D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods for using the same | |
| MX2016015568A (en) | Nucleoside derivatives for the treatment of cancer. | |
| MX2015013021A (en) | 5-bromo-indirubins. | |
| IN2014DN08477A (en) | ||
| IN2014DN07103A (en) | ||
| MX356102B (en) | Compounds and methods for treating leukemia. | |
| WO2014188201A3 (en) | Medicaments for use in methods of treating cancers which comprise a decreased amount of hk36me | |
| EP2836217A4 (en) | Compositions and methods for treatment of the side-effects associated with administration of cancer chemotherapeutic agents | |
| IL235312A0 (en) | Taxane compounds, compositions and methods | |
| MX351961B (en) | Diazonamide analogs. |